Search

Your search keyword '"Jäger, Elke"' showing total 562 results
Start Over Author "Jäger, Elke"
562 results on '"Jäger, Elke"'

1. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Author

Heitmann, Jonas S., Tandler, Claudia, Marconato, Maddalena, Nelde, Annika, Habibzada, Timorshah, Rittig, Susanne M., Tegeler, Christian M., Maringer, Yacine, Jaeger, Simon U., Denk, Monika, Richter, Marion, Oezbek, Melek T., Wiesmüller, Karl-Heinz, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Schroeder, Sarah M., Hoenisch Gravel, Naomi, Scheid, Jonas, Märklin, Melanie, Henrich, Annika, Klimovich, Boris, Clar, Kim L., Lutz, Martina, Holzmayer, Samuel, Hörber, Sebastian, Peter, Andreas, Meisner, Christoph, Fischer, Imma, Löffler, Markus W., Peuker, Caroline Anna, Habringer, Stefan, Goetze, Thorsten O., Jäger, Elke, Rammensee, Hans-Georg, Salih, Helmut R., and Walz, Juliane S.

Published
2023
Full Text
View/download PDF

2. Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer

Author

Meier, Clara, primary, La Rocca, Gianluca, additional, Nawrot, Virginia, additional, Fißlthaler, Beate, additional, Overby, Sarah J., additional, Hourfar, Kai, additional, Plotz, Guido, additional, Seidl, Christian, additional, Ziegler, Paul, additional, Wild, Peter, additional, Zeuzem, Stefan, additional, Brieger, Jürgen, additional, Jäger, Elke, additional, Battmann, Achim, additional, and Brieger, Angela, additional

Published
2024
Full Text
View/download PDF

3. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Author

Heitmann, Jonas S., Bilich, Tatjana, Tandler, Claudia, Nelde, Annika, Maringer, Yacine, Marconato, Maddalena, Reusch, Julia, Jäger, Simon, Denk, Monika, Richter, Marion, Anton, Leonard, Weber, Lisa Marie, Roerden, Malte, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Hörber, Sebastian, Peter, Andreas, Meisner, Christoph, Fischer, Imma, Löffler, Markus W., Karbach, Julia, Jäger, Elke, Klein, Reinhild, Rammensee, Hans-Georg, Salih, Helmut R., and Walz, Juliane S.

Published
2022
Full Text
View/download PDF

4. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade

Author

Wyss, Nina, primary, Berner, Fiamma, additional, Walter, Vincent, additional, Jochum, Ann-Kristin, additional, Purde, Mette T., additional, Abdou, Marie-Therese, additional, Sinnberg, Tobias, additional, Hofmeister, Kathrin, additional, Pop, Oltin T, additional, Hasan Ali, Omar, additional, Bauer, Jens, additional, Cheng, Hung-Wei, additional, Lütge, Mechthild, additional, Klümper, Niklas, additional, Diem, Stefan, additional, Kosaloglu-Yalcin, Zeynep, additional, Zhang, Yizheng, additional, Sellmer, Laura, additional, Macek, Boris, additional, Karbach, Julia, additional, König, David, additional, Läubli, Heinz, additional, Zender, Lars, additional, Meyer, Britta S., additional, Driessen, Christoph, additional, Schürch, Christian M., additional, Jochum, Wolfram, additional, Amaral, Teresa, additional, Heinzerling, Lucie, additional, Cozzio, Antonio, additional, Hegazy, Ahmed N., additional, Schneider, Tino, additional, Brutsche, Martin H, additional, Sette, Alessandro, additional, Lenz, Tobias L., additional, Walz, Juliane, additional, Rammensee, Hans-Georg, additional, Früh, Martin, additional, Jäger, Elke, additional, Becher, Burkhard, additional, Tufman, Amanda, additional, Nuñez, Nicolas, additional, Joerger, Markus, additional, and Flatz, Lukas, additional

Published
2024
Full Text
View/download PDF

5. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Author

Nelde, Annika, Bilich, Tatjana, Heitmann, Jonas S., Maringer, Yacine, Salih, Helmut R., Roerden, Malte, Lübke, Maren, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Peter, Andreas, Hörber, Sebastian, Traenkle, Bjoern, Kaiser, Philipp D., Rothbauer, Ulrich, Becker, Matthias, Junker, Daniel, Krause, Gérard, Strengert, Monika, Schneiderhan-Marra, Nicole, Templin, Markus F., Joos, Thomas O., Kowalewski, Daniel J., Stos-Zweifel, Vlatka, Fehr, Michael, Rabsteyn, Armin, Mirakaj, Valbona, Karbach, Julia, Jäger, Elke, Graf, Michael, Gruber, Lena-Christin, Rachfalski, David, Preuß, Beate, Hagelstein, Ilona, Märklin, Melanie, Bakchoul, Tamam, Gouttefangeas, Cécile, Kohlbacher, Oliver, Klein, Reinhild, Stevanović, Stefan, Rammensee, Hans-Georg, and Walz, Juliane S.

Published
2021
Full Text
View/download PDF

8. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

Author

Mitwasi, Nicola, Feldmann, Anja, Arndt, Claudia, Koristka, Stefanie, Berndt, Nicole, Jureczek, Justyna, Loureiro, Liliana R., Bergmann, Ralf, Máthé, Domokos, Hegedüs, Nikolett, Kovács, Tibor, Zhang, Congcong, Oberoi, Pranav, Jäger, Elke, Seliger, Barbara, Rössig, Claudia, Temme, Achim, Eitler, Jiri, Tonn, Torsten, Schmitz, Marc, Hassel, Jessica C., Jäger, Dirk, Wels, Winfried S., and Bachmann, Michael

Published
2020
Full Text
View/download PDF

17. Supplementary Figure 1 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

Author

Karbach, Julia, primary, Neumann, Antje, primary, Brand, Kathrin, primary, Wahle, Claudia, primary, Siegel, Ekkehard, primary, Maeurer, Markus, primary, Ritter, Erika, primary, Tsuji, Takamasa, primary, Gnjatic, Sacha, primary, Old, Lloyd J., primary, Ritter, Gerd, primary, and Jäger, Elke, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 5 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Author

Reis, Bernardo Sgarbi, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Holz, Megan, primary, Ritter, Erika, primary, Nakayama, Eiichi, primary, Ishida, Toshiaki, primary, Obata, Yuichi, primary, Carver, Brett, primary, Scher, Howard, primary, Scardino, Peter T., primary, Slovin, Susan, primary, Subudhi, Sumit K., primary, Reuter, Victor E., primary, Savage, Caroline, primary, Allison, James P., primary, Melamed, Jonathan, primary, Jäger, Elke, primary, Ritter, Gerd, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 4 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

Author

Karbach, Julia, primary, Neumann, Antje, primary, Brand, Kathrin, primary, Wahle, Claudia, primary, Siegel, Ekkehard, primary, Maeurer, Markus, primary, Ritter, Erika, primary, Tsuji, Takamasa, primary, Gnjatic, Sacha, primary, Old, Lloyd J., primary, Ritter, Gerd, primary, and Jäger, Elke, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Author

Reis, Bernardo Sgarbi, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Holz, Megan, primary, Ritter, Erika, primary, Nakayama, Eiichi, primary, Ishida, Toshiaki, primary, Obata, Yuichi, primary, Carver, Brett, primary, Scher, Howard, primary, Scardino, Peter T., primary, Slovin, Susan, primary, Subudhi, Sumit K., primary, Reuter, Victor E., primary, Savage, Caroline, primary, Allison, James P., primary, Melamed, Jonathan, primary, Jäger, Elke, primary, Ritter, Gerd, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 4 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Author

Reis, Bernardo Sgarbi, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Holz, Megan, primary, Ritter, Erika, primary, Nakayama, Eiichi, primary, Ishida, Toshiaki, primary, Obata, Yuichi, primary, Carver, Brett, primary, Scher, Howard, primary, Scardino, Peter T., primary, Slovin, Susan, primary, Subudhi, Sumit K., primary, Reuter, Victor E., primary, Savage, Caroline, primary, Allison, James P., primary, Melamed, Jonathan, primary, Jäger, Elke, primary, Ritter, Gerd, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 3 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Author

Reis, Bernardo Sgarbi, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Holz, Megan, primary, Ritter, Erika, primary, Nakayama, Eiichi, primary, Ishida, Toshiaki, primary, Obata, Yuichi, primary, Carver, Brett, primary, Scher, Howard, primary, Scardino, Peter T., primary, Slovin, Susan, primary, Subudhi, Sumit K., primary, Reuter, Victor E., primary, Savage, Caroline, primary, Allison, James P., primary, Melamed, Jonathan, primary, Jäger, Elke, primary, Ritter, Gerd, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 2 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Author

Reis, Bernardo Sgarbi, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Holz, Megan, primary, Ritter, Erika, primary, Nakayama, Eiichi, primary, Ishida, Toshiaki, primary, Obata, Yuichi, primary, Carver, Brett, primary, Scher, Howard, primary, Scardino, Peter T., primary, Slovin, Susan, primary, Subudhi, Sumit K., primary, Reuter, Victor E., primary, Savage, Caroline, primary, Allison, James P., primary, Melamed, Jonathan, primary, Jäger, Elke, primary, Ritter, Gerd, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Methods and Figure Legend from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

Author

Karbach, Julia, primary, Neumann, Antje, primary, Brand, Kathrin, primary, Wahle, Claudia, primary, Siegel, Ekkehard, primary, Maeurer, Markus, primary, Ritter, Erika, primary, Tsuji, Takamasa, primary, Gnjatic, Sacha, primary, Old, Lloyd J., primary, Ritter, Gerd, primary, and Jäger, Elke, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Author

Reis, Bernardo Sgarbi, primary, Jungbluth, Achim A., primary, Frosina, Denise, primary, Holz, Megan, primary, Ritter, Erika, primary, Nakayama, Eiichi, primary, Ishida, Toshiaki, primary, Obata, Yuichi, primary, Carver, Brett, primary, Scher, Howard, primary, Scardino, Peter T., primary, Slovin, Susan, primary, Subudhi, Sumit K., primary, Reuter, Victor E., primary, Savage, Caroline, primary, Allison, James P., primary, Melamed, Jonathan, primary, Jäger, Elke, primary, Ritter, Gerd, primary, Old, Lloyd J., primary, and Gnjatic, Sacha, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 3 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

Author

Karbach, Julia, primary, Neumann, Antje, primary, Brand, Kathrin, primary, Wahle, Claudia, primary, Siegel, Ekkehard, primary, Maeurer, Markus, primary, Ritter, Erika, primary, Tsuji, Takamasa, primary, Gnjatic, Sacha, primary, Old, Lloyd J., primary, Ritter, Gerd, primary, and Jäger, Elke, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 2 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

Author

Karbach, Julia, primary, Neumann, Antje, primary, Brand, Kathrin, primary, Wahle, Claudia, primary, Siegel, Ekkehard, primary, Maeurer, Markus, primary, Ritter, Erika, primary, Tsuji, Takamasa, primary, Gnjatic, Sacha, primary, Old, Lloyd J., primary, Ritter, Gerd, primary, and Jäger, Elke, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure Legends 1-12, Table Legends 1-4, Results from Cancer Vaccine Enhanced, Non–Tumor-Reactive CD8+ T Cells Exhibit a Distinct Molecular Program Associated with “Division Arrest Anergy”

Author

Beyer, Marc, primary, Karbach, Julia, primary, Mallmann, Michael R., primary, Zander, Thomas, primary, Eggle, Daniela, primary, Classen, Sabine, primary, Debey-Pascher, Svenja, primary, Famulok, Michael, primary, Jäger, Elke, primary, and Schultze, Joachim L., primary

Published
2023
Full Text
View/download PDF

40. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

Author

Nuñez, Nicolas Gonzalo, primary, Berner, Fiamma, additional, Friebel, Ekaterina, additional, Unger, Susanne, additional, Wyss, Nina, additional, Gomez, Julia Martinez, additional, Purde, Mette-Triin, additional, Niederer, Rebekka, additional, Porsch, Maximilian, additional, Lichtensteiger, Christa, additional, Kramer, Rafaela, additional, Erdmann, Michael, additional, Schmitt, Christina, additional, Heinzerling, Lucie, additional, Abdou, Marie-Therese, additional, Karbach, Julia, additional, Schadendorf, Dirk, additional, Zimmer, Lisa, additional, Ugurel, Selma, additional, Klümper, Niklas, additional, Hölzel, Michael, additional, Power, Laura, additional, Kreutmair, Stefanie, additional, Capone, Mariaelena, additional, Madonna, Gabriele, additional, Cevhertas, Lacin, additional, Heider, Anja, additional, Amaral, Teresa, additional, Hasan Ali, Omar, additional, Bomze, David, additional, Dimitriou, Florentia, additional, Diem, Stefan, additional, Ascierto, Paolo Antonio, additional, Dummer, Reinhard, additional, Jäger, Elke, additional, Driessen, Christoph, additional, Levesque, Mitchell Paul, additional, van de Veen, Willem, additional, Joerger, Markus, additional, Früh, Martin, additional, Becher, Burkhard, additional, and Flatz, Lukas, additional

Published
2023
Full Text
View/download PDF

44. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Author

Harbeck, Nadia, Saupe, Steffen, Jäger, Elke, Schmidt, Marcus, Kreienberg, Rolf, Müller, Lothar, Otremba, Burkhard Joerg, Waldenmaier, Dirk, Dorn, Julia, Warm, Mathias, Scholz, Michael, Untch, Michael, de Wit, Maike, Barinoff, Jana, Lück, Hans-Joachim, Harter, Philipp, Augustin, Doris, Harnett, Paul, Beckmann, Matthias W., Al-Batran, Salah-Eddin, and On behalf of the PELICAN Investigators

Published
2017
Full Text
View/download PDF

46. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

Author

Einsele, Hermann, Engelhardt, Monika, Tapprich, Christoph, Müller, Jürgen, Liebisch, Peter, Langer, Christian, Kropff, Martin, Mügge, Lars O., Jung, Wolfram, Wolf, Hans‐Heinrich, Metzner, Bernd, Hart, Christina, Gramatzki, Martin, Hertenstein, Bernd, Pfreundschuh, Michael, Rösler, Wolf, Fischer, Thomas, Maschmeyer, Georg, Kanz, Lothar, Hess, Georg, Jäger, Elke, Bentz, Martin, Dürk, Heinz A., Salwender, Hans, Hebart, Holger, Straka, Christian, and Knop, Stefan

Published
2017
Full Text
View/download PDF

47. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Author

Ylösmäki, Erkko, Ylösmäki, Leena, Fusciello, Manlio, Martins, Beatriz, Ahokas, Petra, Cojoc, Hanne, Uoti, Arttu, Feola, Sara, Kreutzman, Anna, Ranki, Tuuli, Karbach, Julia, Viitala, Tapani, Priha, Petri, Jäger, Elke, Pesonen, Sari, Cerullo, Vincenzo, Division of Pharmaceutical Biosciences, ImmunoViroTherapy Lab, Drug Research Program, TRIMM - Translational Immunology Research Program, HUSLAB, Divisions of Faculty of Pharmacy, Division of Pharmaceutical Chemistry and Technology, Pharmaceutical biophysics group, and Digital Precision Cancer Medicine (iCAN)

Subjects
317 Pharmacy, T cell activation, 3122 Cancers, oncolytic vaccine, CD40L, Original Article, PeptiCRAd, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, OX40L
Abstract

Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules, including various cytokines or chemokines. Here, we have developed a novel adenovirus encoding two immunostimulatory molecules: cluster of differentiation 40 ligand (CD40L) and tumor necrosis factor receptor superfamily member 4 ligand (OX40L). This novel virus, designated VALO-D102, is designed to activate both innate and adaptive immune responses against tumors. CD40L affects the innate side by licensing antigen-presenting cells to drive CD8+ T cell responses, and OX40L increases clonal expansion and survival of CD8+ T cells and formation of a larger pool of memory T cells. VALO-D102 and its murine surrogate VALO-mD901, expressing murine OX40L and CD40L, were used in our previously developed PeptiCRAd cancer vaccine platform. Intratumoral administration of PeptiCRAd significantly increased tumor-specific T cell responses, reduced tumor growth, and induced systemic anti-cancer immunity in two mouse models of melanoma. In addition, PeptiCRAd therapy, in combination with anti-PD-1 immune checkpoint inhibitor therapy, significantly improved tumor growth control as compared to either monotherapy alone., Graphical Abstract, Ylösmäki et al. develop an oncolytic adenovirus expressing immunostimulatory cytokines OX40L and CD40L. This virus was tested in a peptide-based cancer vaccine platform called PeptiCRAd. Intratumoral administration of PeptiCRAd induced systemic and intratumoral tumor-specific T cell responses, reduced tumor growth, and sensitized tumors to immune checkpoint inhibitor therapy.

Published
2021

48. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Author

Walz, Juliane, primary, Heitmann, Jonas, additional, Tandler, Claudia, additional, Marconato, Maddalena, additional, Habibzade, Timursah, additional, Rittig, Susanne, additional, Tegeler, Christian, additional, Nelde, Annika, additional, Maringer, Yacine, additional, Jäger, Simon, additional, Denk, Monika, additional, Richter, Marion, additional, Oezbek, Melek, additional, Wiesmüller, Karl-Heinz, additional, Bauer, Jens, additional, Rieth, Jonas, additional, Wacker, Marcel, additional, Schroeder, Sarah, additional, Gravel, Naomi Hoenisch, additional, Märklin, Melanie, additional, Henrich, Annika, additional, Klimovich, Boris, additional, Clar, Kim, additional, Lutz, Martina, additional, Holzmayer, Samuel, additional, Hoerber, Sebastian, additional, Peter, Andreas, additional, Meisner, Christoph, additional, Fischer, Imma, additional, Löffler, Markus, additional, Peuker, Caroline, additional, Habringer, Stefan, additional, Goetze, Thorsten, additional, Jäger, Elke, additional, Rammensee, Hans-Georg, additional, and Salih, Helmut, additional

Published
2022
Full Text
View/download PDF

49. A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals

Author

Luo, Ji, Klett, Jennifer, Gabert, Jörg, Lipp, Thomas, Karbach, Julia, Jäger, Elke, Borte, Stephan, Hoffmann, Ralf, Milkovska-Stamenova, Sanja, Luo, Ji, Klett, Jennifer, Gabert, Jörg, Lipp, Thomas, Karbach, Julia, Jäger, Elke, Borte, Stephan, Hoffmann, Ralf, and Milkovska-Stamenova, Sanja

Abstract

There is an ongoing need for high-precision serological assays for the quantitation of anti-SARS-CoV-2 antibodies. Here, a trimeric SARS-CoV-2 spike (S) protein was used to develop an ELISA to quantify specific IgG antibodies present in serum, plasma, and dried blood spots (DBS) collected from infected patients or vaccine recipients. The quantitative S-ELISA was calibrated with international anti-SARS-CoV-2 immunoglobulin standards to provide test results in binding antibody units per mL (BAU/mL). The assay showed excellent linearity, precision, and accuracy. A sensitivity of 100% was shown for samples collected from 54 patients with confirmed SARS-CoV-2 infection more than 14 days after symptom onset or disease confirmation by RT-PCR and 58 vaccine recipients more than 14 days after vaccination. The assay specificity was 98.3%. Furthermore, antibody responses were measured in follow-up samples from vaccine recipients and infected patients. Most mRNA vaccine recipients had a similar response, with antibody generation starting 2–3 weeks after the first vaccination and maintaining positive for at least six months after a second vaccination. For most infected patients, the antibody titers increased during the second week after PCR confirmation. This S-ELISA can be used to quantify the seroprevalence of SARS-CoV-2 in the population exposed to the virus or vaccinated.

Published
2022

50. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial

Author

Al-Batran, Salah-Eddin, Homann, Nils, Pauligk, Claudia, Illerhaus, Gerald, Martens, Uwe M., Stoehlmacher, Jan, Schmalenberg, Harald, Luley, Kim B., Prasnikar, Nicole, Egger, Matthias, Probst, Stephan, Messmann, Helmut, Moehler, Markus, Fischbach, Wolfgang, Hartmann, Jörg T., Mayer, Frank, Höffkes, Heinz-Gert, Koenigsmann, Michael, Arnold, Dirk, Kraus, Thomas W., Grimm, Kersten, Berkhoff, Stefan, Post, Stefan, Jäger, Elke, Bechstein, Wolf, Ronellenfitsch, Ulrich, Mönig, Stefan, and Hofheinz, Ralf D.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results